These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 9278190)

  • 41. Regionally selective deficits in uptake sites for glutamate and gamma-aminobutyric acid in the basal ganglia in schizophrenia.
    Simpson MD; Slater P; Royston MC; Deakin JF
    Psychiatry Res; 1992 Jun; 42(3):273-82. PubMed ID: 1353892
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia.
    Tsai G; van Kammen DP; Chen S; Kelley ME; Grier A; Coyle JT
    Biol Psychiatry; 1998 Oct; 44(8):667-74. PubMed ID: 9798069
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Electrophysiological interactions between striatal glutamatergic and dopaminergic systems.
    West AR; Floresco SB; Charara A; Rosenkranz JA; Grace AA
    Ann N Y Acad Sci; 2003 Nov; 1003():53-74. PubMed ID: 14684435
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dopamine gating of glutamatergic sensorimotor and incentive motivational input signals to the striatum.
    Horvitz JC
    Behav Brain Res; 2002 Dec; 137(1-2):65-74. PubMed ID: 12445716
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence.
    Carlsson A; Waters N; Holm-Waters S; Tedroff J; Nilsson M; Carlsson ML
    Annu Rev Pharmacol Toxicol; 2001; 41():237-60. PubMed ID: 11264457
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Deficits of neuronal glutamatergic markers in the caudate nucleus in schizophrenia.
    Nudmamud-Thanoi S; Piyabhan P; Harte MK; Cahir M; Reynolds GP
    J Neural Transm Suppl; 2007; (72):281-5. PubMed ID: 17982904
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The phencyclidine-glutamate model of schizophrenia.
    Halberstadt AL
    Clin Neuropharmacol; 1995 Jun; 18(3):237-49. PubMed ID: 8635182
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Thalamo-cortical communication, glutamatergic neurotransmission and neural oscillations: A unique window into the origins of ScZ?
    Pratt J; Dawson N; Morris BJ; Grent-'t-Jong T; Roux F; Uhlhaas PJ
    Schizophr Res; 2017 Feb; 180():4-12. PubMed ID: 27317361
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Altered cortical glutamate neurotransmission in schizophrenia: evidence from morphological studies of pyramidal neurons.
    Lewis DA; Glantz LA; Pierri JN; Sweet RA
    Ann N Y Acad Sci; 2003 Nov; 1003():102-12. PubMed ID: 14684438
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The glutamatergic dysfunction hypothesis for schizophrenia.
    Coyle JT
    Harv Rev Psychiatry; 1996; 3(5):241-53. PubMed ID: 9384954
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The pathomorphology of schizophrenia and mood disorders: similarities and differences.
    Baumann B; Bogerts B
    Schizophr Res; 1999 Sep; 39(2):141-8; discussion 162. PubMed ID: 10507525
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of cariprazine on extracellular levels of glutamate, GABA, dopamine, noradrenaline and serotonin in the medial prefrontal cortex in the rat phencyclidine model of schizophrenia studied by microdialysis and simultaneous recordings of locomotor activity.
    Kehr J; Yoshitake T; Ichinose F; Yoshitake S; Kiss B; Gyertyán I; Adham N
    Psychopharmacology (Berl); 2018 May; 235(5):1593-1607. PubMed ID: 29637288
    [TBL] [Abstract][Full Text] [Related]  

  • 53. GABA and glutamate in schizophrenia: a 7 T ¹H-MRS study.
    Marsman A; Mandl RC; Klomp DW; Bohlken MM; Boer VO; Andreychenko A; Cahn W; Kahn RS; Luijten PR; Hulshoff Pol HE
    Neuroimage Clin; 2014; 6():398-407. PubMed ID: 25379453
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synaptic dysfunction in schizophrenia.
    Yin DM; Chen YJ; Sathyamurthy A; Xiong WC; Mei L
    Adv Exp Med Biol; 2012; 970():493-516. PubMed ID: 22351070
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pilocarpine-induced status epilepticus causes acute interneuron loss and hyper-excitatory propagation in rat insular cortex.
    Chen S; Fujita S; Koshikawa N; Kobayashi M
    Neuroscience; 2010 Mar; 166(1):341-53. PubMed ID: 20018232
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of central glutamatergic neurotransmission in the pathogenesis of psychiatric and behavioral disorders.
    Wang SJ; Yang TT
    Drug News Perspect; 2005 Nov; 18(9):561-6. PubMed ID: 16421629
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Abnormal striatal expression of transcripts encoding NMDA interacting PSD proteins in schizophrenia, bipolar disorder and major depression.
    Kristiansen LV; Meador-Woodruff JH
    Schizophr Res; 2005 Oct; 78(1):87-93. PubMed ID: 16023328
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of chronic amphetamine treatment on the glutamate concentration in cerebrospinal fluid and brain: implications for a theory of schizophrenia.
    Kim JS; Kornhuber HH; Brand U; Menge HG
    Neurosci Lett; 1981 Jun; 24(1):93-6. PubMed ID: 6115345
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alterations of the dopaminergic and glutamatergic neurotransmission in adult rats with postnatal ibotenic acid hippocampal lesion.
    Schroeder H; Grecksch G; Becker A; Bogerts B; Hoellt V
    Psychopharmacology (Berl); 1999 Jul; 145(1):61-6. PubMed ID: 10445373
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vivo presynaptic control of dopamine release in the cat caudate nucleus--II. Facilitatory or inhibitory influence of L-glutamate.
    Chéramy A; Romo R; Godeheu G; Baruch P; Glowinski J
    Neuroscience; 1986 Dec; 19(4):1081-90. PubMed ID: 2881227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.